Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Cerebrovascular Control in Hypoxia and Hypercapnia
NCT03066115Phase 1Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NG-monomethyl-L-arginine, ketorolac and ascorbic acid (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Change in cerebral blood flow velocity in the middle cerebral artery. Planned start Dec 2020; status: withdrawn.
02
Drugs
NG-monomethyl-L-arginineketorolacascorbic acid
Beyond the preview
Go deeper on NCT03066115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066115.